Skip to main content

DSIP vs Cerebrolysin

Both DSIP and Cerebrolysin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

DSIP

Evidence C

Delta Sleep-Inducing Peptide

A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.

View full DSIP profile →

Cerebrolysin

Evidence B

Cerebrolysin (porcine brain peptide complex)

A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.

View full Cerebrolysin profile →

Side-by-Side

AttributeDSIPCerebrolysin
Evidence GradeCB
FDA StatusNot FDA-approved — research compoundNot FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia
Typical Dose100–300 mcg before bed (subcutaneous)Trial range: 5–30 mL daily (intravenous infusion)
Clinics Indexed3841
Categoriessleep, neuroprotectioncognitive, neuroprotection

Key reported benefits — DSIP

  • Slow-wave-sleep signals (preclinical)
  • Stress/cortisol modulation
  • Possible analgesic effect

Key reported benefits — Cerebrolysin

  • Stroke recovery support
  • TBI rehabilitation
  • Cognitive function in dementia

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons